Cancer is a leading cause of death, and the fibrinolytic system shows cooperative effects that facilitate the growth of tumors and the appearance of metastases. This prospective study aimed to evaluate the fibrinolytic potential in cancer patients and its association with mortality outcomes using the fluorometric method of simultaneous thrombin and plasmin generation. The study included 323 cancer patients and 148 healthy individuals. During the 12-month follow-up, 68 patients died. Compared to the control group, cancer patients showed alterations in thrombin production consistent with a hypercoagulability profile, and an increase in plasmin generation. Mortality risk was associated with two parameters of thrombin in both univariate and multivariable analysis: maximum amplitude (Wald 11.78,p< 0.001) and area under the curve (Wald 8.0,p< 0.005), while such associations were not observed for plasmin. In conclusion, this was the first study able to demonstrate the simultaneous evaluation of thrombin and plasmin generation in newly diagnosed untreated cancer patients. Patients with cancer have been observed to exhibit a hypercoagulable profile. During the study, two parameters linked to thrombin generation, MA and AUC, were identified and found to have a potential association with mortality risk. However, no associations were found with parameters related to plasmin generation.
癌症是导致死亡的主要原因之一，纤溶系统在促进肿瘤生长和转移发生方面显示出协同效应。本研究采用同步凝血酶与纤溶酶生成的荧光测定法，旨在前瞻性评估癌症患者的纤溶潜能及其与死亡结局的关联。研究纳入323例癌症患者及148名健康对照者。在12个月的随访期间，共有68例患者死亡。与对照组相比，癌症患者表现出符合高凝状态的凝血酶生成改变，以及纤溶酶生成的增加。在单变量和多变量分析中，死亡风险与凝血酶的两个参数相关：最大振幅（Wald 11.78, p<0.001）和曲线下面积（Wald 8.0, p<0.005），而纤溶酶参数未观察到此类关联。综上所述，本研究首次实现了对新诊断未治疗癌症患者凝血酶与纤溶酶生成的同步评估。观察发现癌症患者存在高凝状态特征。研究期间确定了与凝血酶生成相关的两个参数——最大振幅和曲线下面积，并发现其与死亡风险存在潜在关联，但未发现与纤溶酶生成参数的相关性。
Association of Fibrinolytic Potential and Risk of Mortality in Cancer Patients
肿瘤(癌症)患者之家